Combination therapy offers improved visual outcome compared with anti-VEGF monotherapy, trial finds
“Use of a novel anti-platelet-derived growth factor therapy in concert with ranibizumab resulted in a statistically significant improvement in visual outcome vs. ranibizumab monotherapy for the treatment of wet age-related macular degeneration, according to a press release from Ophthotech…” Retinal Consultants of AZ is committed to clinical research and the pursuit of new and improved… Read More »
- Posted on: Jun 13 2012